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Capsid-targeted viral inactivation (CTVI), a promising gene-based antiviral strategy against retroviruses, was designed to
disrupt the retroviral life cycle by incorporating a degradative enzyme (e.g., nuclease) into viral particles during assembly,
thereby reducing or eliminating the production of infectious virus. The experimental system used to develop the CTVI
strategy for retroviruses is designed to block the production of infectious Moloney murine leukemia virus (Mo-MLV). Two
nucleases, Escherichia coli ribonulease HI and Staphylococcus nuclease, have been shown to be tolerated by the cell as
Mo-MLV Gag-nuclease fusion polyproteins and still be active in the viral particles. The goal of this study was to determine
what cellular and viral factors limit CTVI in cultured cells. The avian DF-1 cell line greatly expanded our ability to test the
antiviral efficacy of CTVI in long-term assays and to determine the mechanism(s) of CTVI action. The CTVI antiviral effect is
dependent on the level of Mo-MLV Gag-nuclease fusion polyprotein expressed. The Mo-MLV Gag-nuclease polyproteins
produce a long-term prophylactic antiviral effect after a low- or high-dose Mo-MLV challenge. The Mo-MLV Gag-nuclease
fusions have a significant therapeutic effect (;1000-fold) on the production of infectious Mo-MLV. The therapeutic CTVI
effect can be improved by a second delivery of the CTVI fusion gene. Both the prophylactic and the therapeutic CTVI antiviral
approaches can virtually eliminate the production of infectious Mo-MLV in vitro and are only limited by the number of cells
in the population that do not express adequate levels of the CTVI fusion polyprotein. © 2000 Academic PressINTRODUCTION
Capsid-targeted viral inactivation (CTVI) is a promising
gene-based antiviral strategy against retroviruses
(Boeke and Hahn, 1996). Novel approaches for increas-
ing the cell’s resistance to retroviral pathogens are
needed since retroviruses typically do not elicit a protec-
tive immune response, have a high rate of genetic vari-
ation, and have been refractory to most drug treatments.
CTVI disrupts the retroviral life cycle by incorporating a
degradative enzyme (e.g., nuclease) into viral particles
during assembly, thereby reducing or eliminating the
production of infectious virus. Retroviral Gag polypro-
teins can assemble into viral particles in the absence of
other viral proteins (Craven and Parent, 1996; Swanstrom
and Wills, 1997). We and others have shown that if
foreign proteins fused to Gag polyproteins are supplied
in trans, they are incorporated into viral particles during
retroviral assembly (Hansen et al., 1990; Jones et al.,
1990; Natsoulis et al., 1995; Schumann et al., 1996; Van-
Brocklin et al., 1997; Wang et al., 1994; Weldon et al.,
1990). An incorporated Gag-nuclease polyprotein fusion
has direct access to the viral nucleic acid, causing tar-
1 To whom correspondence and reprint requests should be ad-
ressed at Molecular Medicine Program, Mayo Foundation, 200 First
treet, SW, Rochester, MN 55905. Fax: (507) 266-2122. E-mail:
ederspiel.mark@mayo.edu.
111geted degradation. One advantage of incorporating a
degradative enzyme into virions is that even relatively
inefficient delivery of the Gag-degradative enzyme fusion
may be effective since, at least in theory, one active
degradative enzyme could disable a virion. Two nucle-
ases, Escherichia coli ribonulease HI (RH) and Staphy-
lococcus nuclease (SN), have been shown to be toler-
ated by the cell as Gag-nuclease fusions and still be
active in the viral particles. The nucleases have sub-
strate specificities and/or activity restrictions that limit
their activity in the host cell. RH is an endonuclease with
a very narrow substrate specificity (Crouch, 1990; Post et
al., 1993). RH recognizes only RNA–DNA hybrids, digest-
ing only the RNA strand of the duplex. An RNA–DNA
hybrid of the viral genome is an intermediate of retrovirus
replication (Telesnitsky and Goff, 1997). SN is a broad-
spectrum nuclease (RNA, DNA, single-strand, double-
strand) that requires calcium for activity (0.5–1 mM for
optimal activity) (Tucker et al., 1978). It is normally se-
creted by Staphylococcus to cleave extracellular nucleic
acid. Since intracellular calcium levels are #1 mM in
most cells, SN is presumably inactive within the host cell
but active in the virion. Fusion of the degradative enzyme
to Gag may also sequester the degradative enzyme from
possible undesired cellular substrates through normal
Gag polyprotein transport to the plasma membrane and
assembly into virions.
The experimental system used to develop the CTVI
0042-6822/00 $35.00
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112 VANBROCKLIN AND FEDERSPIELstrategy for retroviruses is designed to block the produc-
tion of infectious Moloney murine leukemia virus (Mo-
MLV) (Natsoulis et al., 1995; Schumann et al., 1996, 1997;
VanBrocklin et al., 1997). The Mo-MLV gag gene encodes
a 65-kDa polyprotein precursor which is proteolytically
processed into four structural proteins by the Mo-MLV
protease; MA (matrix)-p12-CA (capsid)-NC (nucleocap-
sid) (Craven and Parent, 1996; Hansen et al., 1990; Swan-
strom and Wills, 1997). The Mo-MLV gag-nuclease fusion
genes encode a polyprotein in which Mo-MLV Gag is
fused to the nuclease at the carboxy terminus of NC
(MA-p12-CA-NC-nuclease). This results in the insertion
of the nuclease into the core of the particle where the
nuclease would have access to the viral genome. The
CTVI fusion genes were delivered to and expressed in
chicken embryo fibroblasts (CEF) by the RCAS family of
replication-competent avian leukosis virus (ALV)-based
retroviral vectors (Federspiel and Hughes, 1997). This
vector efficiently produces populations of CEF stably
expressing the Mo-MLV Gag-nuclease polyproteins. We
initially demonstrated the efficacy of the CTVI antiviral
approach against Mo-MLV prophylactically, where CEF
expressing the Mo-MLV Gag-SN polyprotein inhibited
the production and spread of the amphotropic Mo-MLV
strain Mo(4070A) ;30-fold compared to control cultures
(Natsoulis et al., 1995). Therapeutically, the Mo-MLV
Gag-SN polyprotein reduced the production of infectious
Mo(4070A) ;20-fold in CEF chronically infected with
Mo(4070A) (Schumann et al., 1996; VanBrocklin et al.,
1997). We then demonstrated that Mo-MLV Gag-RH fu-
sion polyproteins could also elicit a prophylactic and
therapeutic antiviral effect on the production of infectious
Mo(4070A) (VanBrocklin et al., 1997). The antiviral effect
of the Mo-MLV Gag-SN and Mo-MLV Gag-RH fusion
polyproteins were dependent on nuclease activity; the
Mo-MLV Gag polyprotein alone, or SN and RH Gag
fusions that contain active site mutations that abolish
nuclease activity, do not produce significant antiviral
effects. CEF cell culture conditions that optimized viral
and CTVI gene expression significantly improved the
prophylactic antiviral effects of both the RH and the SN
fusion polyproteins inhibiting infectious M0(4070A) pro-
duction ;1500-fold (VanBrocklin et al., 1997). However,
even under these improved conditions the therapeutic
antiviral effect only reduced the production of infectious
virus 10- to 30-fold in CEF chronically infected with
Mo(4070A).
While the CTVI experimental system has many advan-
tages, the limited life span of CEF restricted the system
to relatively short-term experiments. Most permanent
avian cell lines are unsatisfactory for many ALV studies
due to the poor growth of ALV and/or the presence of
interfering exogenous and/or endogenous viruses. How-
ever, a continuous, nontransformed EV-0 chicken cell
line, DF-1, has recently been described that does not
have these limitations (Himly et al., 1998; Schaefer-Kleinet al., 1998). We have shown that the RCAS retroviral
vectors and Mo(4070A) replicate to as high or higher
titers in DF-1 cells compared to CEF (Schaefer-Klein et
al., 1998). The DF-1 cell line enables long-term studies as
well as the production of clonal cell lines expressing
exogenous genes and efficient replication of ALV and
MLV.
The goal of this study was to determine what cellular
and viral factors limit CTVI in cultured cells. Using the
DF-1 cell line, we set out to answer several questions
that arose from our previous studies. Even though CTVI
produced a significant prophylactic antiviral effect, the
Mo(4070A) titers were increasing at the end of the ex-
periment when the CEF cultures became senescent and
ceased replication (VanBrocklin et al., 1997). What is the
final prophylactic antiviral effect? Were the cultures pro-
ducing Mo(4070A) resistant to CTVI? Even under opti-
mum conditions for the expression of viral and CTVI
genes in CEF, only a modest therapeutic antiviral effect
was achieved. What factor(s) limit the therapeutic effect
of CTVI? We report here that the level of the CTVI antiviral
effect was related to the efficiency of delivery of the CTVI
fusion genes and the expression levels of the CTVI
fusion polyprotein. We obtained a significant therapeutic
antiviral effect (.1000-fold) on the production of infec-
tious Mo(4070A) in chronically infected DF-1 cells. Long-
term prophylaxis and therapy assays demonstrated that
the CTVI fusion polyproteins produced a stable inhibition
of Mo(4070A) replication and did not induce selection of
a minor cell population.
RESULTS
Experimental approach. The RCAS vectors used to
express the Mo-MLV Gag-nuclease gene fusions have
been described (Natsoulis et al., 1995; VanBrocklin et al.,
1997). The Mo-MLV Gag-RH and Mo-MLV Gag-SN gene
fusions encode an essentially wild-type Mo-MLV Gag
polyprotein fused to the nuclease at the carboxy-termi-
nus of NC (Fig. 1). The Mo-MLV Gag construct encodes
the wild-type Gag polyprotein and was used as a control.
For most experiments, the high-titer RCASBP(A) vector
(Federspiel and Hughes, 1997) was used to deliver the
CTVI fusion genes and express maximum levels of the
CTVI fusion polyproteins in DF-1 cells. The DF-1 cell line
made it possible to propagate infected cell populations
long term and to generate clonal cell lines. Two experi-
mental approaches have been designed to quantitate the
effects of CTVI: a prophylactic approach which measures
the ability of the Mo-MLV Gag-nuclease polyproteins to
inhibit the spread of a subsequent MLV challenge and a
therapeutic approach which measures the ability of the
CTVI fusion to reduce the production of infectious virus
in cells chronically infected with Mo-MLV. The assays
used Mo(4070A) as the challenge virus. Mo(4070A) is an
engineered amphotropic Mo-MLV hybrid that contains
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113ANTIVIRAL EFFICACY OF Mo-MLV GAG-NUCLEASE FUSIONSthe env gene of the amphotropic 4070A MLV strain (Ott et
l., 1990, 1992).
The CTVI antiviral effect is dependent on the level of
o-MLV Gag-nuclease fusion expressed. To determine
he CTVI effect on Mo(4070A) spread in DF-1 cells, a
rophylaxis assay was done with cells expressing Mo-
LV Gag-RH, Mo-MLV Gag-SN, or Mo-MLV Gag polypro-
eins and with mock-infected cells. All genes were de-
ivered by the replication-competent RCASBP(A) vector.
ector propagation was initiated by transfection of plas-
id DNA that contained an infectious proviral form of the
ector. Maximum levels of the Mo-MLV Gag, Mo-MLV
ag-RH, and Mo-MLV Gag-SN polyproteins were ob-
erved 14–18 days posttransfection (Fig. 2A), which ap-
roximately coincided with peak RCASBP(A) replication
data not shown). The infected DF-1 cultures were chal-
enged with a low dose [multiplicity of infection (m.o.i.) of
.05–0.10 ffu/cell] of Mo(4070A) and passaged for 18
ays. Infectious Mo(4070A) in the culture supernatants
as quantitated at the indicated timepoints by the S1L2
ocus assay (Fig. 2B). As expected, there was little or no
ffect on the rate of Mo(4070A) replication or the final
iter in the control Mo-MLV Gag culture compared to
ock-treated DF-1 cultures. However, the cultures that
xpressed Mo-MLV Gag-RH or Mo-MLV Gag-SN
olyproteins significantly inhibited Mo(4070A) replication
Fig. 2B). The antiviral effect of the Mo-MLV Gag-RH and
o-MLV Gag-SN polyproteins on Mo(4070A) replication
n the DF-1 cultures resulted in significantly less cleaved
o-MLV CA (Fig. 2C) and NC (Fig. 2D) proteins com-
ared to control cultures. The presence of the NC-RH
nd NC-SN fusion proteins in the virions (Fig. 2D) is
FIG. 1. A schematic representation of the CTVI fusion gene cons
Gag-nuclease fusion junctions are shown: the control Mo-MLV Gag, M
are compared to the wild-type Mo-MLV Gag-Pol junction.irect evidence of the coassembly of the Mo-MLV
ag-RH and Mo-MLV Gag-SN polyproteins with the
b
Mo(4070A) Gag and Gag-Pol polyproteins and a subse-
uent cleavage of the CTVI fusion polyprotein by the
o(4070A) protease. Protease cleavage of the coas-
embled Pr85 and Pr65 precursor polyproteins also re-
ults in reduced levels of uncleaved polyproteins (com-
are Figs. 2A and 2C).
As had been shown previously (VanBrocklin et al.,
997), expressing the Mo-MLV Gag-RH or Mo-MLV
ag-SN polyproteins in CEF significantly inhibited the
roduction and spread of Mo(4070A) compared to mock-
reated CEF, 2000- and 4000-fold, respectively. However,
xpressing the Mo-MLV Gag-RH or Mo-MLV Gag-SN
olyproteins in DF-1 cells produced a significantly higher
ntiviral effect on Mo(4070A) replication compared to
ock-treated DF-1, 90,000- and 120,000-fold, respec-
ively, which is 30- to 45-fold higher than in CEF. The
ncrease in antiviral effect was most likely due to the
ncrease in the level of CTVI fusion polyproteins, since
he DF-1 cultures expressed 2-fold higher levels of Mo-
LV Gag-RH or Mo-MLV Gag-SN polyproteins compared
o CEF cultures (data not shown). Although the RCASBP
elivery system produced cultures that expressed high
evels of the CTVI fusion polyproteins, one should keep
n mind that in such mass-infected cultures, the expres-
ion level of the population is an average of the individ-
al cells that express different levels of protein, presum-
bly because individual cells have proviruses in different
hromosomal sites.
The Mo-MLV Gag-nuclease polyproteins produce a
ong-term prophylactic antiviral effect. To determine if the
CASBP(A) delivery and expression of the CTVI fusion
olyproteins in DF-1 cultures produced a long-term inhi-
contained in the ALV-based RCASBP retroviral vector. The Mo-MLV
Gag-RH, and Mo-MLV Gag-SN nucleotide and amino acid sequencestructsition of Mo(4070A) replication, the antiviral effect of the
o-MLV Gag-RH polyprotein was quantitated in a low-
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114 VANBROCKLIN AND FEDERSPIELdose prophylaxis assay passaged for 62 days. Infectious
Mo(4070A) in the culture supernatants was quantitated
by the S1L2 focus assay (Fig. 3A). The culture express-
ing Mo-MLV Gag-RH polyproteins stably inhibited
Mo(4070A) replication throughout the experiment (titer
#10 ffu/ml), while the control cultures produced stable,
high Mo(4070A) titers (titers $105 ffu/ml) after day 14.
The level of the Mo-MLV Gag-RH polyprotein expressed
was stable throughout the experiment, while the control
cultures expressed stable levels of the Mo(4070A) Gag
proteins after day 14 as analyzed by Western immuno-
blots (data not shown). The cultures expressing Mo-MLV
Gag or Mo-MLV Gag-RH polyproteins expressed stable
levels of RCASBP Gag proteins throughout the experi-
ment (data not shown).
To test if the long-term prophylaxis assay induced cell
selection, the relative levels of the RCASBP(A) and
Mo(4070A) proviral sequences in DNA isolated from the
cultures prior to Mo(4070A) challenge, and at days 16, 32,
and 50 postchallenge, were analyzed by Southern trans-
fer. An internal viral fragment and one of the viral host
junction fragments of RCASBP(A) proviruses in BglII-
digested genomic DNA were detected with 32P-labeled
CASBP gag sequences (Fig. 3Ba). An internal viral frag-
ent and one of the viral host junction fragments of
FIG. 2. Prophylactic antiviral effect of the Mo-MLV Gag-nuclease fusio
by the replication-competent RCASBP(A) retroviral vector in DF-1 cells:
(RH); and RCASBP(A)Mo-MLV Gag-SN (SN). (A) Virions were pelleted
proteins were denatured, separated by 12% SDS–PAGE, and analyzed b
dilution), and the bound protein complexes were visualized by chemil
Gag-SN polyproteins (Pr85) and the ;65-kDa Mo-MLV Gag polyprotein
fusion polyproteins were challenged with a low dose of Mo(4070A) (m.
infectious Mo(4070A) by the S1L2 focus assay. Mock (filled diamonds
(circles). (C and D) Immunoblots of viral proteins of day 18 postchallen
The filter was first probed with anti-MLV CA serum (1:5000 dilution) (C),
dilution) (D). The bound protein complexes were visualized by chemil
protein, the NC-RH fusion protein (;27 kDa), and the NC-SN fusion po(4070A) proviruses in HindIII-digested genomic DNA
ere detected with 32P-labeled Mo(4070A) env se-
c
suences (Fig. 3Bc). Both Southern blots were stripped of
heir viral probes and subsequently probed with a 32P-
abeled chicken glyceraldehyde-3-phosphate dehydro-
enase (GAPDH) DNA fragment to control for DNA con-
entration (Figs. 3Bb and 3Bd). No obvious differences in
he RCASBP(A) proviral copy number were observed in
he RCASBP(A)Mo-MLV Gag- or RCASBP(A)Mo-MLV
ag-RH-infected cultures over the course of the experi-
ent (Figs. 3Ba and 3Bb). Each culture challenged with
o(4070A) maintained approximately the same
o(4070A) proviral copy number throughout the experi-
ent (e.g., Gag P, 16, 32, and 50: Figs. 3Bc and 3Bd).
owever, the culture expressing the Mo-MLV Gag-RH
olyproteins contained a significantly lower number of
o(4070A) proviruses compared to the control cultures
Figs. 3Bc and 3Bd). This finding is consistent with the
ulture producing a low level of infectious Mo(4070A)
Fig. 3A) and may indicate that the culture contains cells
ot infected with Mo(4070A) and/or cells that have ac-
umulated a lower number of Mo(4070A) proviruses.
ector and Mo(4070A) RNA levels were analyzed by
Nase protection assay as another test of cell selection.
he levels of RCASBP(A) gag RNA and Mo(4070A) env
NA in the individual cell cultures were stable through-
ut the 62-day experiment (data not shown). We con-
roteins. The Mo-MLV Gag fusion genes were delivered and expressed
treated (M); RCASBP(A)Mo-MLV Gag (G); RCASBP(A)Mo-MLV Gag-RH
ml of each culture supernatant before Mo(4070A) challenge, and the
ern immunoblot. The filter was probed with anti-MLV CA serum (1:5000
cence. The locations of the ;85-kDa Mo-MLV Gag-RH and Mo-MLV
re indicated. (B) DF-1 cultures expressing control or CTVI Mo-MLV Gag
.05–0.10 ffu/cell) at day 0. Infected cell supernatants were analyzed for
LV Gag (squares); Mo-MLV Gag-RH (triangles); and Mo-MLV Gag-SN
phylaxis assay culture supernatants (see B) were prepared as above.
d of bound antibody, and then probed with anti-MLV NC serum (1:5000
cence. The ;30-kDa MLV CA protein (C) and the ;10-kDa MLV NC
;28 kDa) (D) are indicated. Molecular sizes are in kilodaltons.n polyp
mock
from 5
y West
umines
(Pr65) a
o.i. of 0
); Mo-M
ge pro
strippeluded from the Southern and RNase protection analy-
es that the CTVI antiviral effect was due to the Mo-MLV
p
f obed w
c
115ANTIVIRAL EFFICACY OF Mo-MLV GAG-NUCLEASE FUSIONSGag-RH polyproteins and not a result of the selection of
a minor cell population.
A similar analysis was done on a long-term prophy-
laxis assay with a culture expressing the Mo-MLV
Gag-SN polyproteins. Both the culture expressing Mo-
MLV Gag-SN polyproteins and the culture expressing
Mo-MLV Gag-RH polyproteins produced nearly identical
antiviral effects over the 62-day experiment (data not
shown). The culture expressed stable levels of Mo-MLV
Gag-SN RNA and polyprotein and contained stable lev-
els of RCASBP and Mo(4070A) proviruses throughout the
experiment (data not shown).
A significant prophylactic antiviral effect was achieved
after a high-dose challenge. What is the prophylactic
effect of the CTVI fusion polyproteins on a high dose
Mo(4070A) challenge? To help interpret the results of a
high-dose prophylaxis assay, clonal cell lines were iso-
lated from the RCASBP(A)-infected cultures expressing
Mo-MLV Gag-RH or Mo-MLV Gag-SN polyproteins. Rep-
resentative clonal cell lines expressing different levels of
the CTVI fusion polyproteins (Fig. 4A), and the original
cell populations infected by the RCASBP(A) CTVI fusion
viruses, were challenged with a high dose of Mo(4070A)
(m.o.i. of ;10 ffu/cell) and passaged for 18 days. Infec-
tious Mo(4070A) in the culture supernatants was quan-
titated by the S1L2 focus assay (Figs. 4B and 4C).
FIG. 3. Long-term prophylactic effect of the Mo-MLV Gag-RH polyp
Mo-MLV Gag polyproteins (squares), or Mo-MLV Gag-RH polyproteins
ffu/cell) in a prophylaxis assay and passaged for 62 days. Infectious Mo
(B) DNA was prepared from the cultures before initiation of the prophy
DNAs were digested with BglII (a and b) or HindIII (c and d), and th
nitrocellulose, and probed with 32P-labeled RCASBP(A) gag sequences
rovirus will yield one internal viral fragment and one viral host flankin
ilters (a and c) were then stripped of the 32P-labeled viral probes and pr
oncentration and quality.Maximum levels of infectious Mo(4070A) were produced
by day 4 in the control cultures (mock, Mo-MLV Gag).Expression of the Mo-MLV Gag-RH or Mo-MLV Gag-SN
polyproteins produced a significant effect on infectious
Mo(4070A) production, decreasing the level of infectious
Mo(4070A) produced at day 6 by 450- and 80-fold, re-
spectively, compared to controls. Five of six clonal cell
lines produced a significantly higher antiviral effect com-
pared to the original cell populations, while one clonal
cell line, SN-2, had a lower antiviral effect (Figs. 4B and
4C). The antiviral effect improved despite most of the
clonal cell lines expressing the CTVI fusion polyprotein
at levels lower than the original population (Fig. 4A). The
antiviral effect of most of the cultures expressing the
CTVI fusion polyproteins continued to increase after day
6 and may be due to a new round of CTVI gene delivery
from RCASBP(A) virions containing Mo(4070A) env gly-
coproteins.
The Mo-MLV Gag-nuclease fusions have a significant
therapeutic effect on the production of infectious
Mo(4070A). The therapeutic effects of the Mo-MLV
Gag-RH and Mo-MLV Gag-SN polyproteins were as-
sayed in DF-1 cells chronically infected by Mo(4070A).
The therapy assay was initiated by transfecting plasmids
containing the RCASBP(A)-CTVI constructs into the
Mo(4070A)/DF-1 cells and passaging the cultures for 92
days. Infectious RCASBP vector virus is produced from
the plasmid DNA and spreads through the culture to
. (A) Mock-treated DF-1 cells (filled diamonds), DF-1 cells expressing
es) were challenged with a low dose of Mo(4070A) (m.o.i. of 0.05–0.10
in the culture supernatants was quantitated by the S1L2 focus assay.
ssay (lane P) and at 16, 32, and 50 days postchallenge. The genomic
ents were separated by agarose gel electrophoresis, transferred to
o(4070A) env sequences (c). Each digested RCASBP(A) or Mo(4070A)
tion fragment of variable size after hybridization with the probes. The
ith 32P-labeled chicken GAPDH sequences (b and d) to control for DNAroteins
(triangl
(4070A)
laxis a
e fragm
(a) or M
g juncdeliver the CTVI gene. Infectious Mo(4070A) in the cul-
ture supernatants was quantitated by S1L2 assay (Fig.
pulatio
116 VANBROCKLIN AND FEDERSPIEL5A). The control cultures (cells mock transfected and
cells expressing Mo-MLV Gag polyproteins) produced
stable levels of infectious Mo(4070A) (;105 ffu/ml)
throughout the experiment. The cultures expressing Mo-
MLV Gag-RH or Mo-MLV Gag-SN polyproteins produced
significantly lower levels of infectious Mo(4070A) reach-
ing the maximum 1000-fold antiviral effect by day 30. The
level of Mo-MLV Gag proteins produced by the cultures
was analyzed by Western immunoblot of the viral pro-
teins contained in the supernatants and remained rela-
tively constant throughout the experiment (data not
shown). The maximum (1000-fold) therapeutic effect was
reached about day 20 if the CTVI fusion genes were
initially delivered by infecting the Mo(4070A)/DF-1 cells
with a viral stock of the RCASBP(A)-CTVI vector instead
of transfecting the plasmids containing the vector ge-
nome (data not shown).
The therapeutic CTVI effect can be improved by a
second delivery of the CTVI fusion gene. As shown
above, retroviral vector delivery of the CTVI fusion genes
yields a cell population that contains individual cells that
express the CTVI fusion polyproteins at different levels.
We hypothesized that a second delivery of the CTVI
fusion gene to the cell population would further reduce
or eliminate the cells that expressed the CTVI fusion
polyprotein at levels too low to have an antiviral effect
and thereby improve the therapeutic CTVI effect. The
second gene delivery was accomplished with
RCASBP(C), an RCASBP vector that uses a different cel-
lular receptor to gain entry into cells. Each day 62 ther-
FIG. 4. Prophylactic antiviral effect of Mo-MLV Gag-nuclease fusion
Mo-MLV Gag-RH or Mo-MLV Gag-SN polyproteins from RCASBP(A) and
dose of Mo(4070A) (m.o.i. of ;10 ffu/cell). (A) A Western immunoblot
challenge was prepared as described in the legend to Fig. 2. The filter
The ;85-kDa Mo-MLV Gag-RH (RH) and Mo-MLV Gag-SN (SN) polyprot
Gag-RH-infected cultures: RCASBP(A)Mo-MLV Gag-RH population (R
Gag-SN-infected cultures: RCASNP(A)Mo-MLV Gag-SN population (SP
challenged culture supernatants were analyzed for infectious Mo(4070A
and DF-1 cells expressing Mo-MLV Gag polyproteins were all assaye
diamonds); Mo-MLV Gag (squares); Mo-MLV Gag-RH population (filled
(C) Mock (filled diamonds); Mo-MLV Gag (squares); Mo-MLV Gag-SN po
(open circles).apy assay culture (Fig. 5A) was infected with the
RCASBP(C)-CTVI gene virus stock containing the samegene construct (e.g., the Mo(4070A)/DF-1 culture ex-
pressing Mo-MLV Gag-RH was infected with RCASBP-
(C)Mo-MLV Gag-RH) and passaged along with the orig-
inal therapy assay cultures for comparison. Infectious
Mo(4070A) in the culture supernatants was quantitated
by the S1L2 focus assay (Fig. 5B). The second delivery
of the Mo-MLV Gag-RH gene to the Mo(4070A)/DF-1
culture expressing Mo-MLV Gag-RH, or the Mo-MLV
Gag-SN gene to the Mo(4070A)/DF-1 culture expressing
Mo-MLV Gag-SN, virtually eliminated the production of
infectious Mo(4070A) (titers #10 ffu/ml). RCASBP(C) in-
fection of the mock Mo(4070A)/DF-1 culture or the sec-
ond delivery of the Mo-MLV Gag gene to the Mo(4070A)/
DF-1 culture expressing Mo-MLV Gag had no effect on
Mo(4070A) production.
In another second gene delivery experiment, the day
62 therapy assay culture expressing Mo-MLV Gag-RH
polyproteins (Fig. 5A) was infected with the RCASBP(C)
vector alone and the RCASBP(C) vector with the Mo-MLV
Gag, Mo-MLV Gag-RH, or Mo-MLV Gag-SN genes. We
hypothesized that introducing RCASBP(C) into the
Mo(4070A)/DF-1 culture expressing the Mo-MLV Gag-RH
polyproteins would result in a new round of infection with
RCASBP(A)Mo-MLV Gag-RH virions containing subgroup
(C) envelope glycoproteins. All of the cultures infected
with the RCASBP(C) vectors produced lower levels of
infectious Mo(4070A), whether or not the vector con-
tained a CTVI-nuclease fusion gene (Fig. 5C), which is
consistent with our hypothesis. However, the greatest
teins on a high-dose Mo(4070A) challenge. DF-1 cultures expressing
cell lines derived from these populations were challenged with a high
ning the viral proteins isolated from the culture supernatants before
bed with the R187 anti-MLV CA monoclonal antibody (1:1500 dilution).
e indicated. The molecular sizes are in kilodaltons. RCASBP(A)Mo-MLV
RH-5 (R5); line RH-7 (R7); and line RH-9 (R9). RCASBP(A)Mo-MLV
SN-3 (S3); line SN-5 (S5); and line SN-2 (S2). (B and C) Mo(4070A)-
S1L2 focus assay. The eight cultures described above (A), DF-1 cells,
ltaneously but are presented in two panels for clarity. (B) Mock (filled
s); RH-5 (open triangles); RH-7 (open circles); and RH-9 (filled circles).
n (open triangles); SN-2 (filled triangles); SN-3 (filled circles); and SN-5polypro
clonal
contai
was pro
eins ar
P); line
); line
) by the
d simu
triangleantiviral effects were consistently achieved with a sec-
ond delivery of either the Mo-MLV Gag-RH or Mo-MLV
M
G
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117ANTIVIRAL EFFICACY OF Mo-MLV GAG-NUCLEASE FUSIONSGag-SN genes, which virtually eliminated the production
of infectious Mo(4070A) (,10 ffu/ml).
The levels of Mo-MLV Gag proteins contained in cul-
ture supernatants of all three therapy assays (Fig. 5)
FIG. 5. Therapeutic antiviral effect of the Mo-MLV Gag-nuclease fus
transfected with plasmid DNA containing the RCASBP(A) vector with t
(circles) genes or mock transfected (diamonds). The therapy assay
supernatants was quantitated by the S1L2 focus assay. (B and C) The
(day 62, A) with RCASBP(C) vectors. Each therapy culture was also mai
first experiment, the cultures were infected with RCASBP(C) containing
(filled diamonds); mock 1 RCASBP(C) alone (open diamonds); Mo-MLV
o-MLV Gag-RH (filled triangles); Mo-MLV Gag-RH 1 RCASBP(C)Mo
ag-SN 1 RCASBP(C)Mo-MLV Gag-SN (filled circles). (C) In the secon
nfected with RCASBP(C) vector alone or containing the control or CTVI g
open triangles); Mo-MLV Gag-RH 1 RCASBP(C) (open circles) Mo-ML
CASBP(C)Mo-MLV Gag-SN (filled circles); and Mo-MLV Gag-RH 1 Rwere analyzed by Western immunoblot probed with anti-
MLV CA serum (Fig. 6I) and anti-MLV NC serum (Fig. 6II).All cultures produced relatively stable levels of Mo-MLV
Gag proteins throughout the assays. The second delivery
of the Mo-MLV Gag-RH gene resulted in higher levels of
the cleaved NC-RH protein (Fig. 6II, lanes Br/r, Cc/r, Cg/r,
yproteins. (A) DF-1 cultures chronically infected with Mo(4070A) were
MLV Gag (squares), Mo-MLV Gag-RH (triangles), or Mo-MLV Gag-SN
s were passaged for 92 days. Infectious Mo(4070A) in the culture
sion genes were delivered a second time to the therapy assay cultures
without treatment as a control. Two experiments were done. (B) In the
me control or CTVI gene delivered in the initial therapy assay. Mock
en squares); Mo-MLV Gag 1 RCASBP(C)Mo-MLV Gag (filled squares);
ag-RH (open triangles); Mo-MLV Gag-SN (open circle); and Mo-MLV
riment, individual Mo-MLV Gag-RH-expressing therapy cultures were
Mock (open diamonds); Mo-MLV Gag (filled squares); Mo-MLV Gag-RH
RH 1 RCASBP(C)Mo-MLV Gag (filled diamonds); Mo-MLV Gag-RH 1
(C)Mo-MLV Gag-RH (filled triangles).ion pol
he Mo-
culture
CTVI fu
ntained
the sa
Gag (op
-MLV G
d expe
enes.
V Gag-Cr/r, and Cs/r) compared to the original therapy assay
(Fig. 6II, lanes Br and Cr) presumably due to an in-
RP
l
p
118 VANBROCKLIN AND FEDERSPIELcreased level of Mo-MLV Gag-RH polyprotein coas-
sembled with Mo(4070A) Gag and Gag-Pol polyproteins
into virions. Unexpectedly, a second delivery of the Mo-
MLV Gag-SN gene did not result in an obvious increase
in the level of NC-SN protein even though the second
delivery reduced the production of infectious Mo(4070A)
(Fig. 6II, compare lane Bs/s to Bs). The level of Mo-MLV
particles in the culture supernatants was determined by
quantitating the level of CA protein produced by the
FIG. 6. Mo-MLV Gag fusion polyprotein expression levels in the three
therapy assays. A Western immunoblot containing the viral proteins
from the therapy culture supernatants was prepared as described in
the legend to Fig. 2. The filter was first probed with the R187 anti-MLV
CA monoclonal antibody (1:1500 dilution) (I), stripped of antibodies, and
then probed with anti-MLV NC serum (1:5000 dilution) (II). Lane P
represents the Mo(4070A) Gag polyprotein expression level of the
chronically infected DF-1 culture before the start of the therapy assay.
(A) The MLV Gag protein expression levels of the initial therapy assay
cultures at day 62 (see Fig. 5A). (B) The MLV Gag protein expression
levels of the first RCASBP(C) delivery therapy assay cultures at day 32
(see Fig. 5B). (C) The MLV Gag protein expression levels of second
RCASBP(C) delivery therapy assay at day 32 (see Fig. 5C). Mock-
transfected (m); RCASBP(A)Mo-MLV Gag (g); RCASBP(A)Mo-MLV
Gag-RH (r); RCASBP(A)Mo-MLV Gag-SN (s); m 1 RCASBP(C) (c/m); g 1
CASBP(C)Mo-MLV Gag (g/g); r 1 RCASBP(C)Mo-MLV Gag-RH (r/r);
s 1 RCASBP(C)Mo-MLV Gag-SN (s/s); r 1 RCASBP(C) (c/r); r 1 RCASB-
(C)Mo-MLV Gag (g/r); and r 1 RCASBP(C)Mo-MLV Gag-SN (s/r). The
ocations of the ;85-kDa Mo-MLV Gag-RH and Mo-MLV Gag-SN
olyproteins (Pr85), the ;65-kDa Mo-MLV Gag polyprotein (Pr65), the
;30-kDa MLV CA protein, the ;10-kDa MLV NC protein, and the
NC-RH (;27 kDa) and the NC-SN (;28 kDa) fusion proteins are
indicated. Molecular sizes are in kilodaltons.Mo(4070A)/DF-1 culture and the therapy assay cultures.
No significant change in the production of Mo-MLV par-ticles by Mo(4070A)/DF-1 culture or the therapy assay
cultures was observed throughout the experiments (data
not shown).
The therapeutic CTVI effect cannot be explained by
cellular selection. To test if the long-term therapy assays
induced cell selection, RNA and DNA isolated from the
Mo(4070A)/DF-1 culture and the cultures of the three
therapy assays (Fig. 5) were analyzed by RNase protec-
tion assay and Southern transfer. The levels of
Mo(4070A) env RNA, RCASBP(A) env RNA, RCASBP(C)
env RNA, and RNAs containing RH were analyzed by
RNase protection assays (Fig. 7). All assays also con-
tained a probe to detect chicken GAPDH RNA to control
for RNA concentration and quality. All therapy assay
cultures expressed approximately the same level of
Mo(4070A) env RNA throughout the experiments (Fig. 7I).
The cultures infected with only the RCASBP(A) vectors
expressed comparable levels of RCASBP(A) env RNA,
but the cultures infected by both RCASBP(A) and
RCASBP(C) vectors expressed higher levels of
RCASBP(A) env RNA (Fig. 7II). The one exception was the
culture infected with both RCASBP(A)- and RCASBP(C)-
expressing Mo-MLV Gag-SN (Fig. 7II, compare lane Bs to
Bs/s) which was also the culture that did not show an
increase in the level of cleaved NC-SN fusion protein
(see Fig. 6II). The cultures infected by both RCASBP(A)
and RCASBP(C) expressed comparable levels of
RCASBP(C) env RNA (Fig. 7III). All of the RCASBP(A)Mo-
MLV Gag-RH-infected cultures expressed stable levels
of Mo-MLV Gag-RH RNA throughout the experiments
(Fig. 7IV). Infection of the RCASBP(A)Mo-MLV Gag-RH
therapy culture with an RCASBP(C) vector resulted in an
increase in the level of Mo-MLV Gag-RH RNA expressed
whether or not the vector contained a CTVI fusion gene
(Fig. 7IV, compare lane Br to Br/r and Cr to Cc/r, Cg/r, Cr/r,
and Cs/r). We hypothesize that the introduction of the
RCASBP(C) vector results in the amplification of the
RCASBP(A)Mo-MLV Gag-RH vector proviruses because
virions containing subgroup (C) envelope glycoproteins
can spread the RCASBP(A)Mo-MLV Gag-RH genome.
The net result was a relative increase in RCASBP(A) env
and RH RNA levels.
To determine if the CTVI experimental system selected
for cells with a lower Mo(4070A) proviral copy number in
the therapy assay cultures, the relative number of
Mo(4070A) proviruses in genomic DNA isolated from the
therapy assay cultures were analyzed by Southern blot
as described earlier. All therapy assay cultures con-
tained Mo(4070A) proviruses at levels comparable with
that seen in the original Mo(4070A)/DF-1 culture (Fig. 8).
The levels of the RCASBP vector proviruses also re-
mained relatively constant after the maximum therapeu-
tic antiviral effect was achieved (;day 30) in the long-
term therapy assay (see Fig. 5A) and throughout each
second delivery therapy assay (data not shown).
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The DF-1 cell line has greatly expanded our ability to
est the antiviral efficacy of CTVI and to determine the
echanism(s) of CTVI action. The DF-1 cell line enabled
he generation of clonal DF-1 cell lines using an expres-
ion plasmid; however, these lines expressed the CTVI
olyproteins at much lower levels compared to cultures
ith the CTVI genes delivered and expressed by
CASBP(A) (data not shown), even though both the ex-
ression plasmid and the RCASBP contained the same
ranscriptional control elements. While it should be pos-
ible to use transfection of an expression plasmid to
roduce DF-1 cell lines that express CTVI polyproteins at
evels comparable to RCASBP infected cultures, it was
lear that gene delivery by infecting with RCASBP(A)
ectors lead to higher levels of expression. However, the
se of retroviral vectors results in a cell population con-
aining individual cells that express different levels of the
xperimental protein presumably because of the effects
f the host genome on expression from the provirus.
lonal cell lines were generated by serial dilution of the
CASBP-infected cultures expressing the CTVI fusion
olyproteins (Fig. 4A). Most of the clonal lines expressed
lower level of the CTVI polyprotein than the average
evel in the original mixed population, but produced a
igher antiviral effect (Figs. 4B and 4C). This suggests
FIG. 8. Mo(4070A) provirus levels in the therapy assay cultures. DNA
was prepared from the therapy assay cultures on the days described in
the legend to Fig. 6. (I) A Southern blot of HindIII digested genomic
DNA was prepared and probed with 32P-labeled Mo(4070A) env se-
quences as described in the legend to Fig. 3. Each digested Mo(4070A)
provirus will yield one internal viral fragment and one viral host flanking
junction fragment of variable size after hybridization with the probe. (II)
The filter (I) was stripped of the 32P-labeled viral probe and probed with
32P-labeled chicken GAPDH sequences to control for DNA concentra-
ion and quality. The lane nomenclature is described in the legend to
ig. 6.FIG. 7. Analysis of RCASBP, Mo(4070A), and RH RNA levels in the
therapy assay cultures. The figure shows autoradiograms of 6% acryl-
amide/7.6 M urea gels used to separate the protected RNA probe frag-
ments produced in RNase protection assays with RNA isolated from each
therapy assay culture on the days analyzed in Fig. 6. Each assay contained
a chicken GAPDH probe as a control for RNA quality and quantity. GAPDH
RNA protects a 200-nt fragment from the 32P-labeled 279-nt full-length
probe. (I) Mo(4070A) env RNA protects a 344-nt fragment from the 404-nt
probe. (II) RCASBP(A) env RNA protects a 375-nt fragment from the 420-nt
probe. (III) RCASBP(C) env RNA protects a 492-nt fragment from the 577-nt
probe. (IV) RH containing RNA protects a 245-nt fragment from the 295-nt
probe. The nucleotide sizes of each full-length probe and the expectedhat the CTVI antiviral effect will be limited by the number
f cells in the population that express the CTVI fusion
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120 VANBROCKLIN AND FEDERSPIELpolyproteins at levels that do not eliminate the produc-
tion of infectious Mo(4070A).
In previous studies using CEF chronically infected with
Mo(4070A), the Mo-MLV Gag-RH and Mo-MLV Gag-SN
polyproteins produced only a modest therapeutic antivi-
ral effect (10- to 30-fold) on the production of infectious
Mo(4070A) (Schumann et al., 1996, 1997; VanBrocklin et
l., 1997). However, the spread of the RCASBP(A) vector
n the Mo(4070A)-infected CEF cultures was limited to
14 days due to senescence of the CEF. The DF-1 cell
ine made it possible to conduct long-term therapy as-
ays, and for the first time a strong therapeutic antiviral
ffect was obtained (.1000-fold; Fig. 5A). However, the
aximum effect was not achieved until day 30 after the
CASBP(A) infection was initiated by plasmid DNA trans-
ection. We had shown previously that CEF cultures pro-
uced maximum levels of an experimental protein from
CASBP(A) 18–20 days after infection was initiated by
ransfecting the infectious molecular clone plasmid DNA
Federspiel and Hughes, 1994). We believe that the short
elay in reaching the maximum antiviral effect is related
o the efficiency of RCASBP(A) spread through the
o(4070A) infected DF-1 culture, since the maximum
ntiviral effect could be obtained in approximately half
he time if the RCASBP(A) infection was initiated with a
irus stock (data not shown). As discussed above, the
ajor factor determining the level of the therapeutic
ntiviral effect was most likely the population of cells
xpressing low levels of the CTVI polyprotein. A second
elivery of the CTVI fusion gene, either directly in the
CASBP(C) vector or indirectly by introducing the sub-
roup (C) env of RCASBP(C) into the culture and produc-
ng pseudotyped particles, increased the expression of
he fusion protein resulting in the near elimination of
nfectious Mo(4070A) (Figs. 5B and 5C).
As would be expected, the level of the CTVI fusion
olyprotein expressed by the cultures was positively
orrelated with the level of antiviral effect in both pro-
hylaxis and therapy assays. RCASBP(A) replicates to
igher titers in DF-1 cells compared to CEF, and conse-
uently the DF-1 cultures expressed higher levels of the
TVI fusion polyproteins (Fig. 2A), which resulted in
igher prophylactic antiviral effects (Fig. 2B). The Mo-
LV Gag-RH polyprotein was consistently expressed at
ower levels in the culture supernatants compared to the
o-MLV Gag-SN polyprotein. This may be due to
CASBP(A)Mo-MLV Gag-RH replicating to a lower titer
ompared to RCASBP(A)Mo-MLV Gag-SN. Even though
he Mo-MLV Gag-RH polyprotein was expressed at lower
evels, expressing the Mo-MLV Gag-RH polyprotein pro-
uced equal or greater antiviral effects in both the low-
nd the high-dose prophylaxis assays and in the therapy
ssays, relative to expressing the Mo-MLV Gag-SN
olyprotein. Higher levels of the protease cleaved NC-RHusion cleavage product was produced compared to
C-SN levels (Fig. 6). One interpretation of this result is
i
ihe Mo-MLV Gag-RH polyproteins are incorporated into
o(4070A) particles more efficiently than the Mo-MLV
ag-SN polyproteins. Alternatively, both the Mo-MLV
ag-RH and the Mo-MLV Gag-SN polyproteins are effi-
iently incorporated into Mo(4070A) particles but the
o-MLV Gag-RH polyprotein is cleaved more efficiently
y the Mo(4070A) protease. Both possibilities may be
ue, in part, to the apparent instability of the Mo-MLV
ag-SN polyprotein. Cell cultures expressing the Mo-
LV Gag-SN polyproteins often contain a relatively high
evel of immunologically related smaller proteins on
estern immunoblots of viral particles in the culture
upernatant (e.g., Fig. 2A); only a fraction of the total
rotein may have antiviral activity.
All antiviral strategies must limit the toxicity of the
ntiviral agent to the host cell. There was no experimen-
al evidence that the Mo-MLV Gag-RH or Mo-MLV
ag-SN polyproteins were cytotoxic to either CEF or
F-1 cells or that the experimental design resulted in a
election against cells expressing the CTVI fusion
olyproteins, the RCASBP vectors, or Mo(4070A). There
ere no apparent changes in the rate of cell division
data not shown); the cellular RNA levels of the CTVI
usion, RCASBP, or Mo(4070A) genes (Fig. 7); or the copy
umber of RCASBP or Mo(4070A) proviruses (data not
hown; Figs. 3B and 8) throughout the long-term prophy-
axis and therapy assays. In addition, no apparent
o(4070A) escape mutants were observed in the as-
ays. We hypothesize that mutations in the Mo-MLV gag
ene capable of circumventing the antiviral effect would
e rare. An escape mutant would require the selection of
mutant Gag that could still assemble normally but
xclude the Gag-nuclease polyprotein from virions or a
rotease variant that could still process the Gag and
ag-Pol polyproteins correctly but inactivate the nucle-
se by cleavage.
In summary, our new results demonstrate that CTVI
olds even greater promise as a gene-based antiviral
trategy. CTVI can virtually eliminate the production of
nfectious Mo(4070A) in prophylactic and therapeutic ap-
roaches in vitro. While the efficacy of CTVI has been
emonstrated with MLV, the strategy should be applica-
le to other retrovirus groups as well as have broader
pplications to other virus families. The application of
his strategy to protect animals from specific viral dis-
ases should be relatively straightforward since trans-
enic technology can be used to introduce genes into
nimals and express foreign proteins without provoking
n immune response. The application of CTVI or any
ther gene-based antiviral strategy to treat viral disease
n humans awaits improvements in gene delivery, gene
xpression, and the methods that would permit tolerance
f foreign proteins by the immune system. This study
lso shows that CTVI can be used as a sensitive exper-mental tool to probe the protein–protein interactions
nvolved in retrovirus assembly and maturation.
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121ANTIVIRAL EFFICACY OF Mo-MLV GAG-NUCLEASE FUSIONSMATERIALS AND METHODS
Constructions. The construction and use of the RCAS
series of replication-competent ALV-based retroviral vec-
tors and adaptor plasmids (Federspiel and Hughes,
1997) and the construction of the genes encoding Mo-
MLV Gag, Mo-MLV Gag-RH, and Mo-MLV Gag-SN have
been described previously (Natsoulis et al., 1995; Van-
Brocklin et al., 1997). The genes were constructed in the
Cla12NCO adaptor plasmid, isolated as ClaI fragments,
and cloned into the unique ClaI site of RCASBP(A), the
RCASBP retroviral vector with a subgroup (A) env (Fig. 1).
or this study, the same ClaI fragments containing the
ene constructs from the adaptor plasmids were cloned
nto the ClaI site of RCASBP(C), the RCASBP vector with
subgroup (C) env (Schaefer-Klein et al., 1998).
Cell culture and virus propagation. DF-1 cells were
rown in DMEM (Gibco/BRL) supplemented with 10%
etal bovine serum (Gibco/BRL), 100 units of penicillin per
illiliter, and 100 mg of streptomycin per milliliter (Quality
Biological, Inc., Gaithersburg, MD) as previously de-
scribed (Schaefer-Klein et al., 1998). DF-1 cultures were
grown at 39°C and passaged 1:3 when confluent. D56
cells (Bassin et al., 1971) were grown at 37°C in modified
McCoy’s 5A medium (Gibco/BRL), supplemented with
10% fetal bovine serum, 2 mM glutamine (Gibco/BRL),
and penicillin/streptomycin as above. D56 cultures were
split when 80–90% confluent.
RCASBP virus propagation was initiated by transfec-
tion of plasmid DNA that contained the retroviral vector
in proviral form. In standard transfections, 10 mg of pu-
rified plasmid DNA was introduced into DF-1 cells by the
calcium phosphate precipitation method (Kingston et al.,
1989). Viral spread was monitored by assaying culture
supernatants for ALV CA protein by Western transfer
analysis. Virus stocks were generated from the cell su-
pernatants. The supernatants were cleared of cellular
debris by centrifugation at 2000 g for 10 min at 4°C and
tored in aliquots at 280°C.
The amphotropic Mo-MLV strain, Mo(4070A), is an
ngineered hybrid Mo-MLV that contains the env gene
and a part of the pol gene of the amphotropic 4070A virus
(Ott et al., 1990, 1992). Mo(4070A) virus stocks were
produced in NIH3T3 mouse cells grown at 37°C in
DMEM (Gibco/BRL) supplemented with 10% calf serum
(Gibco/BRL) and penicillin/streptomycin as above. Infec-
tious virus was quantitated by the S1L2 focus assay
Bassin et al., 1971) on D56 cells. The titers of the
o(4070A) stocks were 1–2 3 106 ffu/ml.
Prophylaxis assay. Cell cultures were transfected with
CASBP/CTVI plasmid DNAs containing the retroviral
ector in proviral form and subsequently passaged to
llow the viruses to completely infect the culture. In-
ected cultures were then challenged either with a low
ose (m.o.i. of 0.05–0.10 ffu/cell) or a high dose (m.o.i. of
10 ffu/cell) of Mo(4070A). The challenged cultures were
w
5assaged to allow Mo(4070A) to spread. Supernatants
ere collected from confluent cultures every 2 days and
tored at 280°C. Infectious Mo(4070A) in the culture
upernatants was quantitated by the S1L2 focus assay.
liquots of cells were also harvested at various times
hroughout the experiments for subsequent DNA and
NA analyses.
Therapy assay. DF-1 cells chronically infected with
o(4070A) were generated by infecting 4 3 106 cells
with 2 3 106 ffu of Mo(4070A) and passaging the cultures
to allow maximum virus spread. The Mo(4070A)/DF-1
culture produced maximum titers of 1–3 3 105 ffu/ml. The
TVI fusion genes were initially delivered into the
o(4070A)-infected cultures by either transfecting the
ells with the RCASBP/CTVI plasmids DNAs or infecting
he cells with 5 ml of virus stock. The cultures were
assaged to allow the RCASBP virus to spread through-
ut the culture. Supernatants were collected from con-
luent cultures every 2 days and stored at 280°C. Infec-
ious Mo(4070A) in the culture supernatants was quan-
itated by the S1L2 focus assay. Aliquots of cells were
lso harvested at various times throughout the experi-
ents for subsequent DNA and RNA analyses.
SDS–PAGE and Western immunoblot analysis. Super-
atants from confluent cultures were cleared of cellular
ebris by centrifugation at 2000 g for 10 min at 4°C.
irions (10 ml of culture supernatant) were pelleted
hrough 1 ml of a 20% sucrose pad (20% sucrose, 100 mM
aCl, 20 mM Tris–Cl, pH 7.5, 1 mM EDTA) by ultracen-
rifugation at 35,000 rpm in a Beckman SW41 rotor for 60
in at 4°C. The viral pellet was resuspended in 100 ml
Laemmli loading buffer (2% SDS, 10% glycerol, 50 mM
Tris–Cl, pH 6.8, 5% b-mercaptoethanol, 0.1% bromophe-
ol blue) and boiled for 5 min. Viral proteins (from 5 ml of
upernatant) were separated by 12% SDS–PAGE and
ither stained directly with Coomassie blue or trans-
erred to a nitrocellulose membrane. Images of the
tained gels were captured with an AlphaImager 2200
Alpha Innotech Corp., San Leandro, CA), and the protein
ands were quantitated with ImageQuant 1.2 software
Molecular Dynamics, Sunnyvale, CA). Purified chymo-
rypsinogen A (Pierce, Rockford, IL) was used to prepare
standard concentration curve.
The Western transfer filters were blocked in phos-
hate-buffered saline (PBS) with 10% nonfat dry milk
NFDM) for 1 h at 25°C. The filters were then rinsed
riefly in rinse buffer (100 mM NaCl, 10 mM Tris–Cl, pH
, 1 mM EDTA, 0.1% Tween 20), and incubated with
nti-MLV serum or monoclonal antibodies in rinse buffer
ontaining 1% NFDM for 1 h at 25°C. MLV CA protein
as detected with either a goat anti-CA polyclonal serum
1:5000 dilution), a gift from A. Rein (NCI, Frederick, MD),
r the rat R187 anti-CA monoclonal antibody (1:1500
ilution) obtained from ATCC (CRL-1912). MLV NC protein
as detected with rabbit anti-NC polyclonal serum (1:
000 dilution), also a gift from A. Rein. The filters were
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122 VANBROCKLIN AND FEDERSPIELwashed extensively with rinse buffer and then incubated
with 50 ng/ml peroxidase-labeled rabbit anti-goat, goat
anti-rat, or goat anti-rabbit IgG (H 1 L) (Kirkegaard and
Perry, Gaithersburg, MD) in rinse buffer with 1% NFDM
for 1 h at 25°C. After extensive washing with rinse buffer,
immunodetection of the protein–antibody–peroxidase
complexes was performed with the Western blot chemi-
luminescence reagent (DuPont NEN, Boston, MA). The
filters were then exposed to Kodak X-Omat film.
Southern blot analysis. DNA was isolated from conflu-
ent DF-1 cultures by standard methods. Aliquots (20 mg)
ere digested with either BglII (for detection for RCASBP
ag) or HindIII (for the detection of Mo(4070A) env) ac-
ording to the manufacturer’s recommendations, and the
ragments were separated by agarose gel electrophore-
is. Gel processing, DNA transfer, hybridization, and
ashing conditions have been described. The Prime-It II
andom primer labeling kit (Stratagene, LaJolla, CA) was
sed to produce the 32P-labeled probes. The RCASBP
proviruses were detected with a 32P-labeled RCASBP
acI–EcoRI fragment (;2 kb) consisting of a portion of
he 59-untranslated region and the majority of the gag
ene (Federspiel and Hughes, 1997). One internal viral
ragment of 2.6 kb and one viral host flanking junction
ragment of variable size (.2 kb) are expected after BglII
igestion of the integrated RCASBP proviral DNA. The
o(4070A) proviruses were detected with a 32P-labeled
Mo(4070A) XbaI–ClaI fragment (;2 kb) consisting of a
portion of the pol gene and the majority of the 4070A env
gene (Ott et al., 1990, 1992). One internal viral fragment of
2 kb and one viral host flanking junction fragment of
variable size (.2 kb) are expected after HindIII digestion
of the integrated Mo(4070A) proviral DNA. After probing
for the proviral DNA, the blots were stripped of labeled
probe and reprobed with a 32P-labeled fragment of the
hicken GAPDH gene [GenBank Accession No. K01458;
ucleotides 163–361 (Panabieres et al., 1984)] to control
or the quantity and quality of the DNA loaded per lane.
RNase protection assay. Total RNA was isolated from
ultured cells by the RNazol B method (Tel-Test, Inc.,
riendswood, TX). Sequence specific probes were
loned into pBluescript KS (Stratagene) as follows: the
CASBP(A) envelope sequence (Schmidt–Ruppin 2A
train) was cloned as a XbaI to SalI fragment [GenBank
ccession No. M14901; nucleotides 671–1046 (Bova et
l., 1986)]; RCASBP(C) envelope sequence (Prague-C
train) was cloned as a BglI to EcoRI fragment [GenBank
ccession No. J02342; nucleotides 5887–6377 (Katz et
l., 1982; Schwartz et al., 1983)]; Mo(4070A) envelope
equence was cloned as a HindIII to NcoI fragment
GenBank Accession No. M33469; nucleotides
120–1454 (Ott et al., 1990)]; and RH sequence was
loned as a BglII to BamHI fragment [GenBank Acces-
sion No. V00337; nucleotides 244–484 (Kanaya and
Crouch, 1983)]. A fragment of the chicken GAPDH gene
[(GenBank Accession No. K01458; nucleotides 163–361(Panabieres et al., 1984)] was used as a control for the
uantity and quality of the RNA. The constructs were
inearized by restriction endonuclease digestion and gel
urified. 32P-labeled antisense RNA probes were synthe-
sized using the RNA transcription kit (Stratagene). The
probes were hybridized with 20 mg of total RNA in 20 ml
ybridization solution (80% formamide, 10 mM sodium
itrate, pH 6.4, 300 mM sodium acetate, pH 6.4, 1 mM
DTA) overnight at 42°C. RNase protection assays were
erformed using the RPA II ribonuclease protection kit
Ambion, Austin, TX). The RNA samples were digested
ith the RNase A/T1 mixture diluted 1:75. The protected
NA probe fragments were separated on a 6% acryl-
mide/7.6 M urea gel and exposed to Kodak X-Omat film.
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